Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo

YANG LIU1, LISA H. BUTTERFIELD3, XIAOHUI FU2, ZHENSHUN SONG1, XIAOPING ZHANG1, CHONGDE LU2, GUANHUI DING1 and MENGCHAO WU2

1Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital Affiliated to Tongji University, Shanghai 200072; 2Department of Hepatobiliary Tumor, Eastern Hepatobiliary Surgery Hospital, Shanghai 200433, P.R. China; 3Departments of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15213, USA

Received November 4, 2010; Accepted December 20, 2010

DOI: 10.3892/ijo.2011.1004

Abstract. α-fetoprotein (AFP), a tumor-associated antigen for hepatocellular carcinoma (HCC), is an established biomarker for HCC. In this study, we created a lentivirus expressing the AFP antigen and investigated the anti-tumor activity of AFP-specific CD8+ T cells, with and without CD4+ T cells, which were activated by either AFP peptide-pulsed or Lentiviral strategy over peptides, and produced IL-2, IFN-γ, TNF-α, perforin and granzyme B, with minimal production of IL-10 (a negative regulator of T cell activation). Both strategies activated AFP-specific T cells, but the lentiviral strategy was superior by several measures. Data also support an impact of CD4+ T cells in supporting anti-tumor activity. In vivo studies in a xenograft HCC tumor model also showed that AFP-specific T cells could markedly suppress HCC tumor formation and morbidity in tumor-bearing nude mice, as well as regulate serum levels of related cytokines and anti-tumor molecules. In parallel with human in vitro T cell cultures, the in vivo model demonstrated superior anti-tumor effects and Th1-skewing with Lenti-AFP-DCs. This study supports the superiority of a full-length antigen lentivirus-based DCs vaccine strategy over peptides, and provides new insight into the design of DCs-based vaccines.

Introduction

Hepatocellular carcinoma (HCC) is one of the main causes of cancer deaths with a global incidence of over 500,000 new cases per year. HCC has a very poor prognosis, and the majority of cases are detected at advanced stages (1). Systemic therapies, including chemotherapy, are largely ineffective. Local-regional therapy other than resection is largely palliative and includes: Yttrium, transcatheter arterial chemoembolization (TACE), cryoablation and radiofrequency ablation (RFA). The recently US FDA-approved drug, sorafenib, improved median overall survival (OS) by 2.8 mo. (10.7 mo. vs. 7.9 mo. in the placebo group) in unresectable, advanced disease patients (2). Therefore, novel approaches are needed, and immunotherapy interventions that directly target tumor specific antigens (TSA) or tumor-associated antigens (TAA) are a current research focus (3). α-fetoprotein (AFP), which belongs to the albuminoid gene family, is a main component of serum during embryonic development. AFP, a 69-kDa single-chain polypeptide, consisting of 591 amino acid residues, is synthesized in the yolk sac, fetal liver, and gastrointestinal tract during pregnancy (4,5). Suppression of AFP synthesis occurs shortly after birth (6), however, 50% to 80% of adult HCC show AFP re-expression (7,8). These observations suggest that inducing AFP-specific immune responses might be an important direction for clinical treatment of HCC.

Dendritic cells (DCs) are acknowledged as the most powerful professional antigen-presenting cells. They are central to the initiation of an immune response and play vital roles in anti-tumor immunity (9,10). Clinical studies have shown that DCs infiltration in solid tumors correlated with better prognosis while impaired DCs function can inhibit immune responses to tumor (11-13). Thus, DC-based tumor immunotherapy may help to reverse aspects of tumor-driven immune dysfunction and promote anti-tumor immunity. Recently, the first DC-related cancer vaccine received US FDA approval for prostate cancer therapy (Dendreon, ‘Provenge’). In order to generate tumor-specific immune responses against HCC, AFP has been targeted by our group and others. Based on our in vitro human T cell assays and HLA-A2 transgenic mouse studies, the human T cell repertoire responds to the human AFP ‘self’ antigen, and four immunodominant and ten subdominant epitopes were identified (14,15).
A pilot clinical trial was performed in which HCC patients received the four immunodominant peptides emulsified in adjuvant. Five of six patients showed an increased circulating frequency of AFP peptide-specific T cells (by MHC tetramer) to at least one of the peptides. IFN-γ ELISPOT results demonstrated development of functional cytokine responses to all four peptides after vaccination. Most of the pre-treatment AFP-specific cells detected by MHC tetramer assays did not synthesize IFN-γ until after vaccination (16). Because murine models testing murine AFP suggest that AFP-based vaccines are capable of reducing tumor growth (15,17,18), a follow-up trial using AFP peptide-pulsed DC was performed. Ten stage III/IV AFP+-HLA-A2.1+ HCC subjects were vaccinated with AFP peptide-pulsed autologous DCs (19). Again, increased frequencies of circulating AFP-specific T cells and of IFN-γ-producing AFP-specific T cells were detected after vaccination. However, this vaccine did not result in objective clinical responses in that group of advanced stage patients.

An analysis of the differentiation status of circulating AFP-specific CD8+ T cells showed an expanded pool of naive and central memory AFP-specific CD8+ T cells in many HCC patients which co-express central and peripheral trafficking markers, indicating only partial differentiation. Peptide-based vaccination (in the AFP peptide/DC trial) led to modest upregulation of activation markers, but most patients showed no shifts to fully differentiated effector or memory cells (20). In order to address the possibility that only low avidity AFP-specific T cells are available in the periphery of humans activated by vaccines, AFP-specific T cell avidity was tested (21) and it was determined that some AFP-specific T cells are of sufficiently high avidity to recognize very low levels of peptide as well as AFP-expressing tumor cells.

Next, to illustrate the potential relevance of both immunodominant and subdominant AFP epitopes, full-length antigen-based strategies were investigated. Full length AFP presentation revealed that HCC patients have detectable frequencies of circulating IFN-γ-producing AFP-specific CD8+ T cells to both immunodominant and subdominant epitopes. The immunodominant and subdominant peptide-specific T cells could be differentially expanded with different modes of antigen presentation (21) and adeno-virally-transduced DCs (AdV/DCs), expressing full-length antigen, were superior to other antigen presentation modes for broad expansion of high frequencies of multiple CD8+ T cell clones. The subdominant epitope-specific CD8+ T cells could also recognize tumor cells and may be important therapeutically.

AdVhAFP-transduced DCs have been shown to efficiently activate AFP-specific CD8+ and CD4+ T cell responses (17,20,22). However, gene transfer mediated by adenovirus has several potential weaknesses. In cells which proliferate, the gene transfer is transient due to the lack of AdV integration. Also, AdV is highly immunogenic, and the transduced DCs process and present virally-derived peptide epitopes which can serve as recall antigens for those environmentally exposed to this virus. Lastly, DCs do not express the Coxackie-Adenovirus Receptor, therefore AdV transduction is not very efficient, requiring a high pfu:cell ratio (MOI), in the range of 500-1,000 to 1. Thus, in this study, we chose a lentivirus vector, which results in permanent transduction due to viral integration, and reduced immunogenicity (23).

Here, we report the cloning and testing of a lentivirus expressing full-length AFP. We find that co-culturing Lentivirus-engineered or peptide-pulsed DCs with human peripheral blood T cells, results in AFP-specific T cell immune responses (proliferation, cytokine production, cytotoxicity). We examined their anti-tumor activity in a HepG2 tumor-bearing nude mouse model and found that Lentivirus-DC promote superior type I, cytotoxic anti-tumor immunity against HCC which is more potent than peptide-pulsed DCs. This study provides new insight for the design of antigen-engineered DCs based trials, and the function of the activated AFP antigen-specific T cells for HCC immunotherapy.

Materials and methods

Healthy donors. All donors were HLA-A*0201 positive according to standard HLA sero-typing and/or genotyping procedures. Informed consent for participating in this study was obtained from all donors.

Animals and cell lines. Nude mice (6-8 weeks old) were purchased from Shanghai Life Scientific Academy (SLSA). Mice were housed under specific pathogen-free conditions. All experiments were carried out according to the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Bioethics Committee of SLSA. The HLA-A2* AFP-expressing HCC cell line HepG2 was obtained from American Type Culture Collection.

Peptide synthesis. Peptides were synthesized by Sangon Biological Engineering Technology and Service Co. (Shanghai, China). Amino acid sequences were confirmed by amino acid analysis and mass spectroscopy. The purity of the peptides was greater than 95%. The peptides used are as follows: AFP154=MKWVESIFL, AFP155=PLFQVPEPV, AFP156=FMNKFIYEI, AFP157=GLSPNLNRFL, AFP159=PVNPGVGQC, AFP442=GVALQTMKQ, AFP347=TMQFEFLNL.

Construction and preparation of recombinant lentiviral vectors. The lentiviral vector, pWPXL-MOD2, which expresses green fluorescent protein (GFP) was used as the backbone for lentiviral vector construction in this study. α-fetoprotein (AFP) coding sequences were amplified by PCR from HepG2 template and both BamH1 and SalI flanking site sequences were introduced. After digestion of PCR products with BamH1 and SalI, the coding sequence for AFP was purified with a gel purification kit (Invitrogen, Carlsbad, CA) following the manufacturer’s instruction. The DNA coding for these proteins were subsequently cloned in pWPXL-MOD2 vector earlier digested with BamH1 and SalI and gel purified. Preparation of lentiviruses was accomplished using the Profection Mammalian Transfection System (Promega) according to manufacturer’s instructions with some modifications. Briefly, cells cultured in DMEM (Gibco-Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (HyClone, Logan, UT), 100 U/ml of penicillin, and 100 mg/ml streptomycin (Gibco-Invitrogen), were co-transfected with appropriate amounts of the lentiviral vector plasmid, pRSv-REV, pMD1g-pRRE, pMD2G, and interfere plasmid. Into these mixtures, 200 µl of
CaCl₂ (2.5 M, pH 7.2) was added. The DNA-calcium complexes were further mixed with 2.000 µl of 2X HEPES buffered solution for 30 min at room temperature. The mixtures were subsequently added to 6 ml culture medium in a 10-cm Petridish containing 293T cells at a density of 60-70%. After 12 h, the medium was replaced with 15 ml of phenol red-free and fetal bovine serum-free Dulbecco's modified Eagle's medium. The supernatant was collected 72 h later and the cell debris was cleared by centrifugation at 3,750 x g for 5 min at 4°C in a bench top centrifuge (Beckman, Fullton, CA). The clear supernatants were filtered through a 0.45-µm filter and then used to infect cells directly or after further concentration by ultra-centrifugation (72,000 x g for 120 min at Beckman ultracentrifuge with the rotor S28), and then resuspended in phosphate buffered saline and kept at -80°C until usage. Viral titers were determined by infecting 293T cells with different dilutions of the vectors and measuring GFP expression by flow cytometry. AFP transgene expression was measured at both RNA (RT-PCR) and protein levels (Fig. 1). Human DCs were transduced at MOI (multiplicity of infection) = 10, and after 72 h, tested for AFP mRNA by real-time PCR with the following primers (Forward: 5'-ATT TGG ATC CCG CCA CCA TGA AGT-3'; Reverse: 5'-AGA CGT CGA CTC ATT AAA CTC AGT-3'). AFP protein was detected by Western blot in human DC using an AFP specific antibody (R&D Systems).

**Generation of DC and DC culture.** DCs were prepared as previously described (24,25). In brief, peripheral blood was drawn by venous puncture or leukapheresis, and lymphocytes were purified by Ficoll (Pharmacia) gradient separation. PBMC (3-4x10⁷) were cultured in T-25 flasks (Costar) in RPMI-1640 in addition with antibiotics and 5-10% human AB serum. After 24 h, culture supernatants were cultured in triplicate in 200 µl of RPMI-1640 in addition with antibiotics and 10% human AB serum. Culture supernatants were harvested and assessed for [³H]-thymidine incorporation. Results are shown as Stimulate Index (SI):

\[
SI = \frac{cpm (sample)}{cpm (control)}
\]

**Cytotoxicity assay.** Cytotoxicity was assessed by MTT assay as previously described (28). In brief, AFP specific CD8⁺ T cells with or without CD4⁺ T cells were co-cultured with equal number of HepG2 cells in triplicate for 24 h. Lymphocytes and target cells cultured with media alone were used as controls. MTT (5 mg/ml) reagent was added 6 h before harvest and then cells were lysed with 100 µl DMSO. Values (A) were read at 570 nm, and the percentage of cytotoxicity was calculated as below: Cytotoxicity (%) = [1-(A_sample-A_lymphocyte control)/A_target cell control)] x100%.

**Cytokine measurement.** Cells (2x10⁷/well) were cultured in triplicate in 200 µl of RPMI-1640 in addition with antibiotics and 10% human AB serum. For proliferation, cells were pulsed with 1 µCi/well [³H]-thymidine for 6 h before harvest and assessed for [³H]-thymidine incorporation. Results are shown as Stimulate Index (SI):

\[
SI = \frac{cpm (sample)}{cpm (control)}
\]

**Lymphocyte proliferation assay.** Cells (2x10⁷/well) were cultured in triplicate in 200 µl of RPMI-1640 in addition with antibiotics and 10% human AB serum. For proliferation, cells were pulsed with 1 µCi/well [³H]-thymidine for 6 h before harvest and assessed for [³H]-thymidine incorporation. Results are shown as Stimulate Index (SI):

\[
SI = \frac{cpm (sample)}{cpm (control)}
\]

**Murine tumor studies.** Tumors were generated by subcutaneous injection of 10⁶ HepG2 cells in 0.1 ml of PBS into the flank of each nude mouse. Mice were divided into four groups according to body weight (10 mice per group): i) Lenti-AFP group, which was simultaneously treated with T cells activated by Lenti-AFP-transduced DC (1x10⁶ per mouse), ii) AFP⁺ group, mice were subcutaneously injected of 10⁶ T cells activated by AFP⁺ or AFP⁺ peptide-pulsed DC, iii) the control group, mice were subcutaneously injected with 200 µl of PBS. After two weeks, tumors were collected for measuring tumor diameter and weight. Serum was used for cytokine profile analysis.

**Tumor treatment in vivo.** When the largest tumor diameter exceeded 3 mm, mice were injected intratumorally with 10⁶ T cells that treated with Lenti-AFP-transduced DC, AFP⁺-pulsed DC, or AFP⁺-pulsed DC in 100 µl PBS. Mice intratumorally injected with 100 µl PBS/mouse were used as the control. Each group contained 10 mice. The mice were
treated once a week for 2 weeks. At the end of the experiment, tumor tissues were collected for measuring tumor diameter and weight. Serum was used for cytokine profile analysis.

**Statistical analysis.** Results are expressed as mean ± SD. One-way analysis of variance followed by Dunnett's post test was used to determine differences between groups where appropriate. p<0.05 was considered significant. Significant differences are noted as "p<0.05, **p<0.01 and ***p<0.001.

**Results**

*Peptide-pulsed and lenti-transduced DCs induce T cell proliferation.* In this study, a lentivirus vector expressing full-length AFP gene was constructed. We first assessed lentivirus transfection-mediated AFP mRNA and protein expression levels. The expression of AFP mRNA over baseline is 5.31 ± 0.11 compared with 18sRNA (Fig. 1A), while at the protein level, AFP expression was positive compared with Lenti-LacZ-transduced group (Fig. 1B). Human DCs were transduced at 77.4% efficiency at lentiviral MOI of 10 (data not shown).

To investigate the ability of Lenti-AFP-transduced DC to promote anti-tumor immune responses, T cell proliferation rate was assessed. We compared two methods of antigen presentation, Lenti-AFP-transduced DC and AFP peptide-pulsed DC. Results show that Lenti-AFP-transduced DC could significantly promote T cell proliferation (Fig. 2), (SI = 3.68±0.07, p<0.01). The proliferation induced by peptide-pulsed DC was slightly inferior to Lenti-AFP-DC, but each peptide-pulsed DC group tested also reached significance (p<0.01) over background. Consistent with our previous report (21), we also observed a pattern of hierarchy of AFP-specific
CD8+ T cell responses between immunodominant epitopes (AFP137, AFP158, AFP325, AFP542) and subdominant epitopes (AFP1, AFP492, AFP547, AFP555) with these healthy donor cells. 

**AFP-specific CD8+ T cells efficiently kill HepG2 cells.** We next evaluated the AFP-specific T cells for cytotoxic function against the HLA-A2+, AFP+ HCC cell line HepG2. HepG2 cells were co-cultured with AFP-specific CD8+ T cells only, or co-cultured with AFP-specific CD8+ T and CD4+ T cells together; at 1 T cell:1 tumor cell. After 24 h (Fig. 3), T cells activated by Lenti-AFP-engineered DC showed the strongest killing activity against HepG2 cells. T cells stimulated with AFP peptide-pulsed DC could efficiently kill target cells as well, while T cells activated by some of the subdominant AFP peptides on DC showed lower killing activity. We did not observe a statistically-significant difference between AFP-specific CD8+ T cells with CD4+ T cells included and AFP-specific CD8+ T cells-only (although killing activity in the presence of CD4+ T cells was slightly higher), indicating that the effect of T cell help in this effector phase assay was small (but reproducible between different experimental groups).

**Cytokine milieu in Lenti-AFP/DC cultures.** In order to characterize the co-culture of AFP-specific CD8+ T and CD4+ T cells with HepG2 cells, and determine whether peptide-pulsed DC and Lenti-AFP-DC induced a different type 1/type 2 and cytotoxicity milieu, we assessed the concentration of several cytokines and effector molecules in co-culture supernatants. Results demonstrated that all DC-activated AFP-specific T cells secreted high levels of type 1 cytokines IL-2, IFN-γ and TNF-α, as well as cytotoxic effector molecules perforin and Granzyme B (Fig. 4). The Lenti-AFP-DC group had the highest levels of these cytotoxic effector molecules, while peptide-pulsed DCs groups had positive, but lower levels. As with the direct killing assay, the differences between CD8+ and CD4+ T cells together and CD8+ T-cells only were small (with both subsets together again yielding slightly higher effector molecule levels) and not statistically significant. Unexpectedly, CD4+ T cell inclusion did not significantly increase the cytokine levels, indicating CD8+ T cells were the sources for these molecules.

Also examined was the regulatory cytokine IL-10 (also known to be produced by HepG2 cells) as well as FasL. Importantly, the peptide/DC had some increased levels of IL-10 in the co-culture with HepG2, while the Lenti-AFP-DC has the lowest level. This may be due to a maturation effect of lentivirus transduction on the DC (which we observed earlier with adenoviral transduction of human DC) (29). The Lenti-
AFP and peptide/DC groups showed no differences for FasL expression (Fig. 4).

**AFP-specific CD8+ T and CD4+ T cells suppress tumor formation and tumor growth in tumor-bearing nude mice.** To further investigate the anti-tumor activity of DC activated AFP-specific T cells in vivo, human HCC xenograft-bearing nude mice were chosen as a model. Because the data above indicated that Lenti-AFP-DCs were superior in general to several peptides pulsed onto DC, and peptides 1-9 and 542-550 were superior among the subdominant (1-9) and immuno-dominant (542-550) peptides, we chose those groups to test in vivo.

First, we investigated the influence of AFP-specific T cells on tumor formation when simultaneously injected. Nude mice were treated by subcutaneous injection of HepG2 cells and AFP-specific CD8+ T cells ± CD4+ T cells (HepG2: T cell=1:1). As shown in Fig. 5A and C, two weeks after tumor injection, (diameter 12.28±3.49 mm; tumor weight 0.478±0.225 g), symptoms was markedly ameliorated in Lenti-AFP and AFP542-treated group (Lenti-AFP: diameter 7.03±2.78 mm, tumor weight 0.228±0.132 g, p<0.01; AFP542: diameter 8.87±3.49 mm, tumor weight 0.298±0.099 g, p<0.05), while AFP1-pulsed DCs activated T cells were less effective at reducing tumor growth.

Next, we examined the influence of AFP-specific T cells on established tumor growth (Fig. 5B and D). When the largest diameter of the injected HepG2 tumor exceeded 3 mm, mice were injected intratumorally with 10^6 AFP-specific CD8+ T cells ± CD4+ T cells. Mice were treated once a week for two weeks. At the end of the experiment, tumors were collected for tumor diameter and weight measures. Results suggested that, in comparison with negative control group, both Lenti-AFP and AFP542-treated groups could significantly reduce the tumor growth rate (p<0.01), consistently, by both measures.

Serum levels of several cytokines and molecules tested in vitro and important for anti-tumor immunity were also assessed. Results demonstrated (Fig. 6), that there were significant increases of systemic IL-2, IFN-γ, TNF-α, perforin and Granzyme B in the three experimental groups, with a similar pattern of hierarchy (p<0.05) to the tumor volumes in Fig. 5, implicating these molecules in the possible mechanism of the T cell anti-tumor effects. Importantly, consistent with in vitro experimental results, the IL-10 level was lowest in the Lenti-AFP-DC treated group. Serum FasL expression did not appear to play a role, in agreement with the in vitro data.

**Discussion**

Antigen presentation is a crucial step of T cell activation. Dendritic cells, which act to initiate immune responses, are the most powerful professional antigen presenting cells. They
are very plastic cells, and are affected by the context in which they are exposed to antigen. Recent studies find that both tumor and the tumor microenvironment, through multiple complex pathways, can adversely affect DC in cancer patients; inhibiting DC maturation, and also reducing or even suppressing their antigen presentation function (30). Tumor can also promote immune tolerance to TAA by inducing the production of regulatory DC (31) and antigen-specific IL-10-producing Treg (32), which can further promote immune escape (33). Therefore, maintaining the appropriate balance between immune tolerance and immune activation is a pivotal focus for immunotherapy. Traditional approaches to DC modulation for improved anti-tumor immunity are mainly based on skewing DC maturation, to promote antigen-specific CD8+ T and CD4+ T cells as well as innate effector responses that have type 1, anti-tumor activity (34-36). Such modified DC maturation methodology includes adding maturation agents like TLR agonists and cytokines to antigen sources like synthetic peptides, tumor homogenates or purified proteins when culturing DC in vitro (14), or directly transferring antigen into DC (17) via plasmids or viral vectors (37). In this study, we investigated the anti-tumor activity of AFP-specific CD8+ T cells, which were activated by AFP antigen, either loaded by MHC class I-restricted peptide-pulsing or lentivirus AFP-engineering of DC in vitro and in vivo. The in vitro experiments demonstrated that AFP-specific CD8+ T cells could proliferate, produce type 1 cytokines and efficiently kill HepG2 hepatocellular cancer cells, while the murine model demonstrated markedly suppressed tumor growth in HCC tumor-bearing nude mice.

We investigated cytokine production involved in anti-tumor immunity and changes induced by the different DC-based vaccines. Our findings demonstrate that AFP-specific T cells have significantly increased levels of IL-2, IFN-γ, TNF-α, perforin, FasL, and Granzyme B, a type 1, cytotoxic antitumor cytokine and effector molecule profile. Moreover, we examined IL-10, a negative regulator of T cell activation and which is up-regulated in HCC patients (38). Many previous studies have shown that addition of IL-10 neutralizing antibody to DC-T cell co-culture systems improves Th1 cell function (39). Such observations imply that reducing the level of IL-10 might have a positive effect on promoting anti-tumor immunity. Here, our results show that AFP-specific CD8+ T cells that are activated by Lenti-AFP-DC could markedly reduce IL-10 production, relative to other antigen loading strategies, like the commonly used peptide-pulsing method. This may be another mechanism for superior T cell activation.

Currently, two primary molecular mechanisms have been shown to play a role in CTL-induced target cell death: the Fas ligand/Fas pathway and the perforin/Granzyme B pathway.
(40). Both induce cell death directly in target cells via caspase activation. Hayashida et al. (41) reported that perforin/Granzyme B played a dominant role on CTL-induced hepatocyte apoptosis. In this study, we examined the levels of perforin/Granzyme B as well as FasL in both the human in vitro culture cell supernatant, as well as in murine serum from the HCC xenograft studies. Our results show that AFP-specific T cells could significantly upregulate both perforin and Granzyme B, while they had little effect on FasL. Thus, we conclude that the anti-tumor activity of the AFP-specific T cells activated both in vitro and in vivo involved the perforin/Granzyme B pathway. Lastly, our results show that AFP-specific CD8+ T cells groups which included CD4+ T cells revealed a reproducible trend towards stronger killing activity. Moreover, there was increased IL-2 production in the experimental groups including CD4+ T cells, indicating that inclusion of the CD4+ T cells have a helper role for the anti-tumor activity.

In summary, the data presented here demonstrate that lentivirus-engineered DC activate AFP-specific T cells, reveal potent in vitro and in vivo anti-tumor activity, and may be a promising approach for HCC immunotherapy in patients.

Acknowledgements

This study was supported by the University of Pittsburgh Cancer Institute and ROI-CA104524 (LHB) and by Shanghai Pu Jiang Talented Person Plan of China #07PJ14004 (YL).

References


